Janux Therapeutics, Inc. (JANX) News
Filter JANX News Items
JANX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
JANX News Highlights
- For JANX, its 30 day story count is now at 2.
- Over the past 26 days, the trend for JANX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest JANX News From Around the Web
Below are the latest news stories about JANUX THERAPEUTICS INC that investors may wish to consider to help them evaluate JANX as an investment opportunity.
An Intrinsic Calculation For Janux Therapeutics, Inc. (NASDAQ:JANX) Suggests It's 44% UndervaluedKey Insights The projected fair value for Janux Therapeutics is US$18.66 based on 2 Stage Free Cash Flow to Equity... |
Does Janux Therapeutics, Inc. (JANX) Have the Potential to Rally 205.5% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 205.5% in Janux Therapeutics, Inc. (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Wall Street Analysts See a 220.17% Upside in Janux Therapeutics, Inc. (JANX): Can the Stock Really Move This High?The consensus price target hints at a 220.2% upside potential for Janux Therapeutics, Inc. (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Janux Therapeutics, Inc. (JANX) Loses -34.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerThe heavy selling pressure might have exhausted for Janux Therapeutics, Inc. (JANX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsSAN DIEGO, November 07, 2023--Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights |
We're Not Very Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
10 Healthcare Stocks with Insider BuyingIn this article, we will take a look at the 10 healthcare stocks with insider buying. To see more such companies, go directly to 5 Healthcare Stocks with Insider Buying. Investors were processing inflation report on August 10 to find clues on the Federal Reserve’s possible moves. CPI’s growth in July was identical to that […] |
Wall Street Analysts Think Janux Therapeutics, Inc. (JANX) Could Surge 120.82%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 120.8% in Janux Therapeutics, Inc. (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Misses Revenue EstimatesJanux Therapeutics, Inc. (JANX) delivered earnings and revenue surprises of 19.23% and 15.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsSAN DIEGO, August 08, 2023--Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights |